Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Dorte Nielsen
- Target Recruit Count
- 39
- Registration Number
- NCT03295084
- Locations
- 🇩🇰
Herlev Hospital, Herlev, Denmark
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients with Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT03290937
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
- Conditions
- Interventions
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT03279237
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen
- Conditions
- Interventions
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2023-04-13
- Target Recruit Count
- 170
- Registration Number
- NCT03279289
- Locations
- 🇪🇸
Spanish Cooperative Group for Digestive Tumour Therapy (TTD), Madrid, Spain
Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Peking University
- Target Recruit Count
- 11
- Registration Number
- NCT03251417
- Locations
- 🇨🇳
Beijing Cancer Hospital / Peking University Cancer Hospital, Beijing, Beijing, China
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03245450
- Locations
- 🇩🇪
Eisai Trial Site 6, Essen, Germany
🇩🇪Eisai Trial Site 1, Aachen, Nordrhein-Westfalen, Germany
🇮🇹Ospedale Infantile Regina Margherita, Torino, Piemonte, Italy
First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS
- Conditions
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 435
- Registration Number
- NCT03231722
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Oncologico Veneto, Padova, Italy
🇮🇹A.O. Universitaria Pisana - Pisa (Pi) Oncologia Medica, Pisa, Italy
🇮🇹Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
- Conditions
- Interventions
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Fujian Cancer Hospital
- Registration Number
- NCT03222089
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 520
- Registration Number
- NCT03206151
- Locations
- 🇨🇳
Cancer hospital Chinese academy of medical sciences, Beijing, Beijing, China
🇨🇳Tianjing medical university cancer institute and hospital, Tianjin, Tianjin, China
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT03189706
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.